Allmed Solutions Achieves Landmark ‘Needle-Stick’ Heart Valve Replacement

OR AKIVA, Israel, Dec. 9, 2025 /PRNewswire/ -- Allmed Solutions (TASE: ALMD), an Israeli biomedical company, has announced a dramatic success in a first-in-human trial, achieving the full replacement of a major heart valve in critically ill patients via a minimally invasive catheterization procedure, entirely eliminating the need for high-risk open-chest surgery.

Allmed Solutions and its subsidiary, TruLeaf Medical, have completed the final stage of a trial for their innovative RoseDoc system. The new technology allows for a diseased heart valve to be fully replaced with a new, functional one, performed solely through a needle stick access point.

The groundbreaking procedure was carried out on two patients suffering from severe heart failure caused by a massive leak in their tricuspid valve (the three-leaflet valve on the right side of the heart). For both patients, conventional medical and surgical options had been exhausted, and their condition was considered too severe to undergo standard open-heart surgery. The investigational treatment was therefore provided under a compassionate care pathway.

Sign up for Blog Updates